HEALTH CARE
- Share via
Biotech Provisions Dropped from Health Reform Bill: House Majority Leader Rep. Richard Gephardt (D-Mo.) has dropped a 15% Medicare rebate requirement for biotechnology companies from his health care reform bill, industry and congressional sources said. Gephardt has also scrapped a commission that would review drug prices to be used in the Medicare program, according to Rep. Anna Eshoo (D-Calif.). The biotech industry has strongly opposed the price commission and the rebate as price controls that would reduce capital investment in the industry and inhibit research.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
